ArticleAIDS and behavior2021
Physical, Emotional, and Psychosocial Challenges Associated with Daily Dosing of HIV Medications and Their Impact on Indicators of Quality of Life: Findings from the Positive Perspectives Study.
Article in AIDS and behavior, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed.
- Rapid Virologic Suppression With Dolutegravir Plus Lamivudine Facilitates Early Switch to Long-Acting Cabotegravir Plus Rilpivirine for Treatment-Naive People With HIV-1: Month 11/12 Outcomes From the Phase 3b VOLITION Study.Open forum infectious diseases · 2026Trial
- A Phase 1 Study to Evaluate the Potential Drug-Drug Interaction Between Islatravir and Lenacapavir.Journal of clinical pharmacology · 2026Trial
- A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High-Concentration, Long-Acting Cabotegravir Formulation in Adults Without HIV.Clinical pharmacology in drug development · 2025Trial
- Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study.Journal of the International AIDS Society · 2022Trial
- Real-World Safety and Effectiveness of Cabotegravir in People Living with HIV: Interim Report of a Post-marketing Surveillance in Japan.Advances in therapy · 2026Article
- Impact of implementation process on long-acting cabotegravir/rilpivirine prescription at 9 HIV clinics, 2021-2024.Journal of acquired immune deficiency syndromes (1999) · 2026Article
- Navigating Through the Caregiving Trajectory: A Qualitative Interview Study on the Challenges Encountered by Primary Caregivers When Caring for Adolescents Living with HIV.Nursing reports (Pavia, Italy) · 2026Article
- Cabotegravir+rilpivirine long-acting every 2 months in a real-world setting: 24-month outcomes in people with HIV-1.AIDS (London, England) · 2026Article
- Combined injectable regimens in treatment-experienced HIV/AIDS patients at a southern academic medical center: a case series.BMC infectious diseases · 2026Article
- Implementation of Long-Acting Cabotegravir/Rilpivirine in US HIV Care Settings: Results From a National Survey of Frontline Clinicians.Open forum infectious diseases · 2026Article
- Real-world adherence, persistence, and health care resource utilization among people with HIV receiving long-acting cabotegravir plus rilpivirine compared with oral antiretroviral therapy in the United States: The ABOVE Study.Journal of managed care & specialty pharmacy · 2026Article
- Evaluation of Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet of Islatravir and Lenacapavir.Journal of clinical pharmacology · 2026Article
- Burden of comorbid disease, treatment, and healthcare utilization among people with HIV: A retrospective, cross-sectional study from a large healthcare organization.Epidemiology and infection · 2026Article
- Polypharmacy in HIV: Rethinking what counts and why it matters.HIV medicine · 2026Review
- Exploring the Treatment Journey of People Living With HIV in Iran: A Qualitative Study.AIDS research and treatment · 2026Article
- Interest in long-acting injectable ART among adolescents with perinatally acquired HIV in Cameroon: Implications for implementation in developing countries.PLOS global public health · 2026Article
- Midwives' views on implementation of antiretroviral clinical guidelines for the prevention of HIV in a private hospital.Health SA = SA Gesondheid · 2026Article
- Chinese healthy eating index as a measure of diet quality and its association with depression and anxiety symptoms among people living with HIV: a cross-sectional study in China.Frontiers in nutrition · 2026Article
- Strategies to Manage Dosing Deviations and Interruptions of Cabotegravir Long-Acting Intramuscular Injections.Clinical pharmacology in drug development · 2026Article
- Preferences of people living with HIV for treatment regimen attributes: a qualitative interview study.Frontiers in public health · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To assess challenges with daily oral antiretroviral therapy (ART), we analyzed data for 2389 participants in the 2019 Positive Perspectives survey of people living with HIV in 25 countries. ART-related challenges reported included difficulty swallowing pills (33.1% [790/2389]); stress from daily dosing routine (33.3% [795/2389]); bad memories from daily intake of HIV medication (35.1%[839/2389]), and concern "that having to take pills every day means a greater chance of revealing my HIV status to others" (37.9% [906/2389]). Individuals who felt empowered by daily oral dosing ["taking my pill(s) every day reassures me that my HIV is being kept under control"] had 69% higher odds of optimal overall health (AOR 1.69, 95% CI 1.40-2.04). Conversely, odds of optimal overall health were lower among those who felt daily pill intake "limits my day-to-day life" (AOR 0.53, 95% CI 0.44-0.64). These findings show that there is need for increased flexibility of ART delivery to meet diverse patient needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.